Tag: ALN-AGT

Alnylam Presents Positive Late-Breaking Data from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension

– Single Doses of Investigational ALN-AGT Achieved Sustained Reductions in Serum Angiotensinogen (AGT) at 12 Weeks Resulting in Reduced Blood Pressure – – Durability of AGT Knockdown Supports the Potential of Once Quarterly or Biannual Dosing – – ALN-AGT was […]